Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
$21.43
-$0.80(-3.25%)
At close: 4:00 PM EST
$21.43
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$12.72 - $32.10
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.73M
Market Cap
$3.30B
Enterprise Value$2.14B
Total Cash (Recent Filing)$598.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 10, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding174,316,830
10 Day Avg. Volume1,728,798
30 Day Avg. Volume1,729,015
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue13.34K
Enterprise Value/Gross Profit-9.93K
Enterprise Value/Ebitda-4.87
Forecast
1Y Price Target
$40.33Price Target Upside88.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Clinical DataMost patients maintained their response after six months off-treatment from batoclimab, and nearly half of responders achieved ATD-free remission, providing evidence of significant clinical benefit.
Phase 3 TrialsThe likelihood of success in Phase 3 is considered greater given the trials were optimized with batoclimab's Phase 2 experience in mind, and patients are receiving higher doses with IMVT-1402.
Treatment PotentialThe totality of data supports FcRn’s potential to be disease modifying in certain refractory patients and offer sustained/durable response enabling patients to go off ATD or reduce.
Bears Say
Competitive Landscape1402 is too far behind in certain indications like myasthenia gravis to gain meaningful market share, with competitor drugs already well-established.
Development RiskThe simplified trial design for chronic inflammatory demyelinating polyneuropathy creates more development risk compared to competitors who have used more robust safeguards.
Market PositionThe company is late to the FcRn market and faces potential financing risks ahead of key value inflecting events due to limited cash reserves.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $12.72 and its highest was $32.10 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $3.30B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Nov 10, 2025 which is in 12 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Aug 11, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.68 by -$0.03.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.71.
How many shares outstanding does Immunovant have?
Immunovant has 174,316,830 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.68. Following the earnings report the stock price went down -4.528%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
Immunovant Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.33 (88.19% Upside)
$40.33 (88.19% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $143.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.90%
12-Months-Change
Fundamentals
Return on Equity
-77.58%
Trailing 12-Months
Asset Growth
12.17%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Stock 12 Month Forecast
Average Price Target
$40.33
▲(88.19% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
58.10% Insiders
14.53% Mutual Funds
0.12% Other Institutional Investors
20.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---